Study Comparing Intranasal Nafarelin and Subcutaneous Triptorelin for Final Egg Maturation in Women with Infertility

3 1 1 1

What is this study about?

This clinical trial is focused on studying infertility, a condition where individuals have difficulty getting pregnant. The study is comparing two treatments used to help mature eggs in the ovaries during a process called ovarian stimulation. The first treatment is an intranasal spray called nafarelin, and the second is a subcutaneous injection called triptorelin. Both treatments are used to trigger the final maturation of eggs, which is an important step in fertility treatments.

The purpose of the study is to compare the effectiveness of these two treatments in helping retrieve mature eggs, known as metaphase II oocytes, during a specific type of fertility treatment cycle called progesterone-primed ovarian stimulation. Participants in the study will receive either the nafarelin nasal spray or the triptorelin injection. The study will monitor the number of mature eggs retrieved, as well as other factors like the total number of eggs collected, any side effects, and the participants’ experiences with the treatments.

The study will take place over a period of time, with participants undergoing the treatment and then having their eggs collected. The researchers will gather data on the outcomes to determine which treatment is more effective or if they are equally effective. This information could help improve fertility treatments for individuals experiencing infertility.

1 joining the trial

Upon joining the study, you will be informed about the trial’s purpose, procedures, and your role as a participant. You will be asked to provide consent to participate in the trial.

2 initial assessment

You will undergo an initial assessment to confirm eligibility. This includes checking your age, body mass index (BMI), and the number of follicles in your ovaries. You must be between 18 and 35 years old, have a BMI between 18 and 30 kg/m2, and have at least 10 follicles of 14mm average diameter.

3 medication administration

You will be randomly assigned to receive either intranasal nafarelin or subcutaneous triptorelin to trigger final oocyte maturation. Nafarelin is administered as a nasal spray, while triptorelin is given as an injection under the skin.

The dosage and frequency of administration will be explained to you by the medical team. The duration of this stage will depend on your specific treatment plan.

4 monitoring and follow-up

After medication administration, you will be monitored for the number of mature eggs (oocytes) retrieved. Blood tests will be conducted to measure hormone levels, including LH, FSH, and progesterone.

You will be asked to report any side effects, pain, or preferences regarding the medication used.

5 completion of trial

Once the trial is completed, you will receive a summary of your participation and any relevant findings. Your feedback on the ease of use and preference for the medication will be collected.

Who Can Join the Study?

  • Age between 18 and 35 years old.
  • Must be an oocyte donor (a person who donates eggs for fertility treatments).
  • Undergoing a progesterone-primed ovarian stimulation cycle (PPOS), which is a specific type of fertility treatment using any available hormone medications to stimulate the ovaries.
  • Body Mass Index (BMI) between 18 and 30 kg/m2. BMI is a measure of body fat based on height and weight.
  • At least 10 follicles (small sacs in the ovaries that contain eggs) with an average diameter of 14mm or more on the last ultrasound before the trigger medication is given.

Who Cannot Join the Study?

  • Participants must not have any medical conditions that could interfere with the study.
  • Participants must not be using any medications that could affect the study results.
  • Participants must not have a history of allergic reactions to any of the study medications.
  • Participants must not be pregnant or breastfeeding.
  • Participants must not have any significant health issues that could pose a risk during the study.
  • Participants must not have participated in another clinical trial recently.
  • Participants must not have any mental health conditions that could affect their ability to participate in the study.
  • Participants must not have any substance abuse issues.
  • Participants must not have any other conditions that the study doctors think would make it unsafe for them to participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Hospital Universitari General De Catalunya Sant Cugat Del Valles Spain
Hospital Universitari Dexeus Grupo Quironsalud Barcelona Spain
Djyjbw Mwdlu Rpql Reus Tarragona Spain
Hezakcdd Qpfmxiwuzem Dsm Vlddpb Sabadell Spain
Drvquf Mokvv Tugrndlbw Tarragona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Spain Spain
Not yet recruiting
15.05.2026

Trial locations

Investigated drugs:

Nafarelin is a medication used in this clinical trial to help mature eggs in the ovaries. It is administered through the nose, which means you spray it into your nostrils. This medication helps trigger the final stage of egg development, making the eggs ready for retrieval in fertility treatments.

Triptorelin is another medication used in the trial for the same purpose as nafarelin. However, it is given as an injection under the skin. Like nafarelin, triptorelin helps the eggs in the ovaries reach their final stage of maturity, so they can be collected for fertility procedures.

Infertility – Infertility is a condition where an individual is unable to conceive after a year of regular, unprotected sexual intercourse. It can affect both men and women and may result from various factors, including hormonal imbalances, structural problems, or issues with sperm or egg production. In women, infertility may be linked to ovulation disorders, blocked fallopian tubes, or uterine abnormalities. In men, it often involves low sperm count, poor sperm motility, or blockages that prevent sperm delivery. The progression of infertility depends on the underlying cause, which may remain stable or worsen over time. Environmental factors, lifestyle choices, and age can also influence the progression of infertility.

Trial ID:
2024-516621-31-00
Protocol code:
FSD-NAF-2024-11
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study on Corifollitropin Alfa and Follitropin Beta for Women with Infertility Undergoing Ovarian Stimulation with Medroxyprogesterone Acetate

    Recruiting

    3 1 1 1
    Investigated diseases:
    Spain
  • Study on the Effect of Metformin on Endometrial Function in Women with Unexplained Infertility

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Poland